Prescriber Scope of Practice for Weight Loss/GLP-1 in Georgia

If you’re a psychiatrist or psychiatric nurse practitioner thinking about adding weight management to your practice — or you’re already fielding patient requests for GLP-1s like Ozempic or Wegovy — you’re navigating a regulatory minefield that most of us weren’t trained for.

Here’s the reality: Yes, psychiatrists can legally prescribe weight-loss medications, including GLP-1 agonists and controlled substances like phentermine, via telehealth in most states. But the devil is in the details — federal DEA rules are in flux, state medical boards have wildly different standards, and your scope of practice as a mental health provider prescribing for obesity isn’t always clear-cut.

This isn’t just academic. Get it wrong and you’re looking at medical board complaints, insurance audits, or worse. Get it right and you can offer real help to patients struggling with antipsychotic-induced weight gain, binge eating disorder, or metabolic syndrome — while building a revenue stream that doesn’t depend on insurance reimbursement games.

Let’s break down what you actually need to know to prescribe weight-loss medications legally and safely via telehealth in 2025-2026.

The Federal Framework: DEA Rules for Telehealth Prescribing (Good News for Now)

The short version: You can prescribe controlled substances via telehealth without an in-person exam through December 31, 2026 — but this is temporary.

Pre-COVID, the Ryan Haight Act required an in-person medical evaluation before prescribing any Schedule II-V controlled substance via telemedicine. During the pandemic, the DEA waived this requirement. That waiver has been extended four times — most recently through the end of 2026 — while the DEA figures out permanent regulations.

What this means practically:

• Right now, you can prescribe phentermine (Schedule IV appetite suppressant) to a new patient via video visit without seeing them face-to-face first
• After 2026, you’ll likely need either a ‘special telemedicine registration’ or meet specific conditions (the DEA proposed rules in January 2025 requiring tele-prescribers of Schedule II stimulants to be in the same state as patients, among other restrictions)
• GLP-1 agonists (semaglutide, tirzepatide) are not controlled substances — you can prescribe them via telehealth indefinitely with no DEA restrictions, as long as you meet standard-of-care requirements

Critical distinction: This federal flexibility doesn’t override stricter state laws. New York, for example, still requires an in-person exam for any controlled substance prescription, federal waiver or not. Always check your state’s rules.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Your Scope of Practice: Can a Psychiatrist Treat Obesity?

As a physician psychiatrist (MD/DO): You have broad prescriptive authority. There’s no separate ‘obesity license.’ If you can demonstrate competence and follow the standard of care, you can legally prescribe weight-loss medications.

Many psychiatrists already do this tangentially — managing antipsychotic-induced metabolic syndrome, treating binge eating disorder, or addressing weight gain from SSRIs. Prescribing a GLP-1 to mitigate olanzapine-related weight gain is well within your wheelhouse.

But here’s the catch: State medical boards will hold you to the same standard as an obesity medicine specialist would follow. That means:

• Documenting BMI and comorbidities
• Obtaining informed consent about medication risks
• Ruling out contraindications (thyroid disease, eating disorders)
• Providing or referring for nutrition/exercise counseling
• Scheduling appropriate follow-ups (often every 3 months minimum)

Florida’s Board of Medicine, for instance, requires written informed consent and quarterly re-evaluations for anyone prescribing weight-loss drugs — psychiatrist or not. New Jersey mandates a psychiatric evaluation before starting obesity medications, recognizing that uncontrolled depression or eating disorders make weight-loss drug therapy unsafe.

For PMHNPs and psychiatric PAs: This is where scope gets murky. Your training and certification are in mental health, not metabolic disorders. Prescribing purely for obesity — especially if there’s no psychiatric indication — might be viewed as practicing outside your scope.

In states like Texas and Florida, you’d need a supervising physician’s sign-off, and that physician should ideally have expertise in obesity treatment (family medicine, endocrinology) — not just another psychiatrist. California’s AB 890 allows experienced NPs to practice independently starting in 2026, but if you’re a psych-certified NP treating obesity, you’re still expected to stay within your competency area or get additional training.

Bottom line for PMHNPs: Either collaborate formally with a primary care or obesity medicine physician, pursue additional certification (like the American Board of Obesity Medicine credential), or limit your weight management to psychiatric patients where there’s a clear mental health connection (binge eating disorder, medication-induced weight gain).

State-by-State Reality Check: Where the Rules Actually Differ

New York: The Strictest Standard

New York essentially ignored the federal DEA waiver. As of May 2025, you cannot prescribe any controlled substance via telehealth to a new patient without an in-person exam — period.

Limited exceptions:

• Another NY provider saw the patient in person within 12 months and shared records
• You’re covering for a colleague who saw the patient face-to-face
• Emergency situation with an established patient (5-day supply max)

What this means: If you want to prescribe phentermine in NY via telehealth, you need to either:

1. See the patient in person first, OR
2. Partner with a local clinic/physician who can do the initial exam

GLP-1s (Ozempic, Wegovy) are not controlled, so you can prescribe them via telehealth in NY freely — but you still need a proper video examination and documentation.

NY also mandates checking the I-STOP PMP database within 24 hours before prescribing any Schedule II-IV controlled substance, and all prescriptions must be e-prescribed (including non-controlled meds).

Florida: Permissive with Strict Documentation Requirements

Florida is more telehealth-friendly but has detailed rules specifically for obesity treatment.

The good news:

• No in-person exam required for telehealth prescribing (including controlled substances, except Schedule II — but weight-loss meds are usually Schedule IV)
• Psychiatrists can prescribe Schedule II stimulants via telehealth if it’s for a psychiatric disorder (ADHD, yes; obesity, no)

The documentation requirements:

• Patient must have BMI ≥30 (or ≥27 with comorbidities)
• Written informed consent required
• Re-evaluation every 3 months minimum if on anti-obesity medications
• Must provide patients with Florida’s ‘Weight-Loss Consumer Bill of Rights’
• Cannot prescribe SSRIs off-label for weight loss (explicitly forbidden by state rule)

Florida also requires checking the E-FORCSE PDMP before prescribing any controlled substance to patients 16+ years old.

For PMHNPs in Florida: You need physician supervision unless you qualify for autonomous practice (which generally requires family practice or primary care certification, not psychiatric). Even with supervision, the supervising physician should have appropriate obesity treatment expertise.

California: Corporate Practice Landmines

California allows telehealth prescribing (including controlled substances) if you conduct an ‘appropriate prior examination’ via video and meet the standard of care.

The telehealth rules:

• Must obtain documented patient consent for telehealth
• Must check CURES PDMP before first controlled substance prescription and every 4 months for ongoing therapy
• All prescriptions must be e-prescribed

The trap: California’s Corporate Practice of Medicine doctrine is the strictest in the country. Only physician-owned professional corporations can provide medical services. A telehealth company owned by non-physicians (venture capital, private equity) cannot employ you directly to provide weight-loss care — it must be structured through a medical professional corporation.

This has killed or restructured dozens of telehealth companies in California. If you’re joining a platform, verify the legal structure carefully.

For NPs: AB 890 phases in independent practice for experienced NPs (3+ years, additional training) starting in 2026. But if you’re a psych NP treating obesity independently, you’re still expected to demonstrate competency in that area.

Texas: Delegation Required, PMP Checks Mandatory

Texas allows telehealth prescribing with no in-person exam requirement, but has strict rules around delegation.

Key requirements:

• Must establish relationship via live video (or store-and-forward with audio)
• NPs and PAs must have a Prescriptive Authority Agreement with a Texas physician that specifically includes weight-loss medications
• Must check Texas PMP (AWARxE) before prescribing controlled substances (required for opioids/benzos; recommended for all controlled drugs)
• Must send a report to patient’s primary care provider within 72 hours (with patient consent)

Texas has historically been aggressive about enforcing prescribing rules. Document everything.

Pennsylvania and Illinois: Federal Rules Apply (For Now)

Both states have no specific ban on telehealth controlled substance prescribing, so the federal DEA extension applies.

Pennsylvania:

• Must check PA PDMP before first opioid/benzo prescription and each time thereafter
• CRNPs (NPs) and PAs need collaborative/supervisory agreements to prescribe
• No state-specific obesity prescribing rules (follow standard medical practice)

Illinois:

• Allows Full Practice Authority for experienced APRNs (4,000+ hours) — they can prescribe Schedule II-V independently
• Must check PMPnow database for Schedule II narcotics
• All controlled substance prescriptions must be e-prescribed (as of Jan 2023)
• Very telehealth-friendly — explicitly allows audio-only in some cases

The Economics: Why Platform Models Make Sense

Here’s where most psychiatrists get it wrong when they try to DIY weight-loss telehealth:

Real patient acquisition costs for weight loss services:

• SEO takes 6-12 months of consistent investment ($2,000-5,000/month in content, technical work, link building) before generating meaningful patient flow
• Google Ads for ‘weight loss doctor’ or ‘GLP-1 prescription’ run $15-40+ per click, with conversion rates often under 5% — you’re looking at $200-400+ cost per booked patient after factoring in wasted clicks and no-shows
• Psychology Today and Zocdoc charge monthly fees ($30-300/month) plus per-booking fees ($35-100), and you’re competing with hundreds of providers on the same page
• Add in staff time to handle inquiries, qualify leads, and deal with no-shows from cold marketing, and your true cost per new patient is easily $300-500+

Most solo practitioners don’t have the budget, expertise, or patience for this.

The platform alternative: Services like Klarity Health use a pay-per-appointment model — you pay a standard listing fee only when a pre-qualified patient actually books with you. No upfront marketing spend, no monthly subscriptions, no gambling on which marketing channel might work.

The value proposition:

• Pre-qualified patients already matched to your specialty and availability
• Zero wasted ad spend — you only pay when patients show up
• Built-in telehealth infrastructure (no separate platform costs, no IT headaches)
• Both insurance and cash-pay flow (diversify your revenue)
• You control your schedule — see patients when you want

Instead of spending $3,000-5,000/month on marketing with uncertain results, you pay per patient you actually see. That’s guaranteed ROI vs. gambling on marketing channels you might not understand.

This is especially valuable for weight-loss services where patient acquisition costs are astronomical and regulatory complexity is high. The platform handles compliance infrastructure, credentialing, and patient matching — you focus on clinical care.

Practical Compliance Checklist

If you’re prescribing weight-loss medications via telehealth, here’s your minimum compliance protocol:

Before the first appointment:

• [ ] Verify you’re licensed in the state where the patient is located
• [ ] Confirm your malpractice insurance covers telehealth and weight management
• [ ] Set up e-prescribing with PDMP integration for your state(s)
• [ ] Create telehealth consent forms specific to your state requirements

During the initial visit:

• [ ] Obtain and document telehealth consent (required in CA, IL, and recommended everywhere)
• [ ] Verify patient identity and location at start of visit
• [ ] Document weight, height, BMI calculation
• [ ] Review medical history including psychiatric medications, cardiovascular risk, thyroid function
• [ ] Screen for contraindications (pregnancy, eating disorders, recent cardiovascular events)
• [ ] Check PDMP if prescribing controlled substances
• [ ] Discuss diet, exercise, behavioral modifications (document this)
• [ ] Provide written informed consent about medication risks
• [ ] Document why telehealth is appropriate for this patient

For controlled substances specifically:

• [ ] Check your state’s PDMP before first prescription (and at intervals required by state law)
• [ ] E-prescribe (required in NY, CA, IL, TX, and many others)
• [ ] Document clinical justification for controlled substance vs. non-controlled alternatives

Ongoing care:

• [ ] Schedule follow-up at intervals required by state law (every 3 months in Florida, more frequent elsewhere)
• [ ] Monitor efficacy and side effects at each visit
• [ ] Re-check PDMP at required intervals (every 4 months in CA for ongoing controlled Rx)
• [ ] Coordinate with patient’s primary care provider (required in some states like Texas)
• [ ] Document each encounter thoroughly — assume your notes will be reviewed

For state-specific requirements:

• Florida: Provide ‘Weight-Loss Consumer Bill of Rights,’ document quarterly re-evaluations
• New York: If prescribing controlled substances, ensure in-person exam within 12 months
• California: Query CURES every 4 months for ongoing controlled therapy
• Texas: Send PCP report within 72 hours (with consent)

Common Questions Answered

Q: Can I prescribe GLP-1s to out-of-state patients?

A: You can prescribe to patients in any state where you hold an active medical license. GLP-1s are not controlled substances, so there’s no federal restriction. But you must follow that state’s telehealth and prescribing laws.

The Interstate Medical Licensure Compact makes it easier to get licensed in multiple states (29 states participate as of 2025). Otherwise, you need individual state licenses.

Q: What if a patient asks for Ozempic specifically because they saw it on social media?

A: Document the conversation. Explain the difference between semaglutide for diabetes (Ozempic) vs. the weight-loss formulation (Wegovy). Discuss realistic expectations — GLP-1s typically produce 10-15% body weight loss over 6-12 months when combined with lifestyle changes.

Set boundaries: you’re prescribing based on medical necessity, not cosmetic preferences. Patients with BMI 27-30 need documented comorbidities (hypertension, diabetes, dyslipidemia) to justify treatment.

Q: Do I need extra certification to prescribe weight-loss medications?

A: No state requires special certification for physicians. However, getting board certification from the American Board of Obesity Medicine (ABOM) strengthens your credibility and demonstrates competency if ever questioned.

For PMHNPs, additional training or certification in obesity medicine is strongly recommended if you’re treating patients without a psychiatric indication.

Q: What happens when the DEA’s telehealth extension expires in 2026?

A: The DEA proposed permanent rules in January 2025 that would allow certain Schedule III-V controlled substance prescribing via telehealth with a ‘special registration,’ and limited Schedule II prescribing for specialists like psychiatrists (with restrictions).

Watch for final rules late 2025/early 2026. Worst case: you’ll need to see new patients in person before prescribing controlled substances, or limit telehealth practice to non-controlled medications (GLP-1s, metformin, etc.).

The Bottom Line

Psychiatrists can absolutely prescribe weight-loss medications via telehealth legally — but you need to:

1. Understand your state’s specific rules (not just federal law)
2. Stay within your competency (get training if you’re venturing outside traditional psych practice)
3. Document like you’re being audited (because you might be)
4. Use the right infrastructure (PDMP access, e-prescribing, proper consent forms)

For most psychiatrists, the smartest move isn’t building a weight-loss practice from scratch — it’s partnering with a platform that handles patient acquisition, compliance infrastructure, and credentialing while you focus on clinical care.

The demand is real. Patients are searching for providers who can prescribe GLP-1s, and many are willing to pay cash. The regulatory complexity is also real. Get the legal and operational framework right, and this can be a sustainable, rewarding addition to your practice.

Ready to start seeing weight-loss patients without the marketing headaches? Join Klarity’s provider network to get matched with pre-qualified patients in your state — no upfront costs, just a per-appointment fee when you actually see patients. We handle credentialing, compliance infrastructure, and patient acquisition so you can focus on providing care.

Citations and References

1. U.S. Department of Health & Human Services. (January 2, 2026). ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act). (2019, accessed November 2025). http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012 – Standards for the Prescription of Drugs to Treat Obesity. (Effective August 8, 2022). https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Law. (March 30, 2024). ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs.’ Client Alert. https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. California Medical Association. (December 2, 2025). ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal.’ https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated